Shifting paradigm of developing biologics for the treatment of pancreatic adenocarcinoma.

about

Shifting paradigm of developing biologics for the treatment of pancreatic adenocarcinoma.

Item

http://www.wikidata.org/entity/Q39453577

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Shifting paradigm of developing biologics for the treatment of pancreatic adenocarcinoma.

@en

Shifting paradigm of developing biologics for the treatment of pancreatic adenocarcinoma.

@nl

type

Item

label

Shifting paradigm of developing biologics for the treatment of pancreatic adenocarcinoma.

@en

Shifting paradigm of developing biologics for the treatment of pancreatic adenocarcinoma.

@nl

prefLabel

Shifting paradigm of developing biologics for the treatment of pancreatic adenocarcinoma.

@en

Shifting paradigm of developing biologics for the treatment of pancreatic adenocarcinoma.

@nl

P1476

Shifting paradigm of developing biologics for the treatment of pancreatic adenocarcinoma.

@en

P2093

Agnieszka A Rucki

http://www.w3.org/2001/XMLSchema#string

Lei Zheng

http://www.w3.org/2001/XMLSchema#string

Xu Che

http://www.w3.org/2001/XMLSchema#string

Ying Zeng

http://www.w3.org/2001/XMLSchema#string

P2860

The Notch pathway is important in maintaining the cancer stem cell population in pancreatic cancer

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

STATs in cancer inflammation and immunity: a leading role for STAT3

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis

CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans

Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

P304

441-448

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.21037/JGO.2016.10.02

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28736631

http://www.w3.org/2001/XMLSchema#string

P921

adenocarcinoma

P932

5506276

http://www.w3.org/2001/XMLSchema#string